Ranking: Best to Worst by Weight Loss Effectiveness
- Retatrutide (24-28.7% weight loss)
Triple agonist (GLP-1/GIP/Glucagon). Best results but not available until 2027-2028. Clinical trials only.
Status: Phase 3 trials - Tirzepatide (15-22.5% weight loss)
Dual agonist (GLP-1/GIP). Best CURRENTLY available option. $179-499/month compounded.
Status: FDA approved, available now - CagriSema (15-20% weight loss estimated)
Dual agonist (Amylin + GLP-1). Novo Nordisk's answer to tirzepatide. Not available yet.
Status: Phase 3 trials, expected 2027 - Survodutide (15-19% weight loss)
Dual agonist (GLP-1/Glucagon). Boehringer Ingelheim. Similar to tirzepatide but years away.
Status: Phase 3 trials, expected 2028+ - Semaglutide (10-15% weight loss)
Single agonist (GLP-1). Proven, safe, 5+ years real-world use. $179-349/month compounded.
Status: FDA approved, available now - Orforglipron (8-15% weight loss)
Oral GLP-1 pill. Convenient (no injections) but less effective than injectable peptides.
Status: Phase 3 trials, expected 2028
Best Overall: Tirzepatide (Available Now)
Why tirzepatide wins:
- ✅ Excellent results (15-22.5% weight loss)
- ✅ Available TODAY through telemedicine
- ✅ Affordable at $179-499/month compounded
- ✅ 2+ years real-world safety data
- ✅ No waiting until 2027-2028
Best Future Option: Retatrutide (2027-2028)
If you can wait 1-2 years, retatrutide will likely be the most effective option. But most people should start tirzepatide NOW and switch later if needed.
Start the Best Available Peptide Today
Tirzepatide: 15-22.5% weight loss, available now, $179/month
Start with MEDVi → Medical Disclaimer: This article is for informational purposes only and does not provide medical advice. GLP-1 medications require a prescription and should be used only under the guidance of a licensed healthcare professional. Always consult your doctor before starting any weight loss medication to ensure it is safe for your specific health history.